New paper from internists calls for increased role for FDA

Sep 24, 2009

A new policy paper that calls for broader authority and increased funding for the Food and Drug Administration (FDA) was released today by the American College of Physicians (ACP). Improving FDA Regulation of Prescription Drugs offers a half-dozen recommendations about how to improve the agency's ability to approve and monitor new drugs.

The paper notes that the FDA has been chronically underfunded, has limited regulatory authority, and insufficient organizational structure to effectively undertake the complex task of regulating the safety and effectiveness of new and approved drugs. This regulating includes reviewing proposals for conducting clinical drug trials, evaluating drug applications and proposed drug labeling, and monitoring drugs once they are approved and marketed.

"The FDA is critical in assuring the available in this country are safe and effective," said Joseph W. Stubbs, MD, FACP, president of ACP. "Unfortunately they have not historically been given the support and structure necessary to be optimally effective."

In 2005, the FDA requested that the Institute of Medicine put together a committee to assess the current state of the U.S. drug safety system and to make recommendations to improve that system. The committee found that FDA's ability to approve and monitor drug safety had been compromised by a lack of regulatory authority, long-standing underfunding, organizational problems, and a lack of postmarketing data on the effectiveness and safety of drugs. Since the report was issued the agency has taken steps to improve, however problems still remain.

In order to effectively improve the agency's ability to regulate drugs, ACP recommends that the FDA:

  • be given increased funding;
  • increase their capacity to regulate drugs manufactured outside the U.S. through appropriations and user fees;
  • be given expanded authority to exercise in the design of preapproval trials and studies;
  • prohibit the bundling of drugs that limits marketability and availability;
  • improve the adverse events reporting system; and,
  • be given the authority to require new drugs be labeled with a symbol that indicates it is a new drug and that direct-to-consumer advertising be limited for the first two years after a drug's approval.
"Physicians and our patients expect that the medications we prescribe and use are beneficial and will not cause significant harm," concluded Dr. Stubbs. "I believe that using the recommendations we have provided today will allow us all to be more secure in that expectation."

Source: American College of Physicians

Explore further: New research demonstrates benefits of national and international device registries

add to favorites email to friend print save as pdf

Related Stories

Off-label use: Oft not evidence based

Aug 21, 2009

In a recent national survey, a substantial minority of physicians erroneously believed that certain off-label uses of prescription drugs were approved by the Food and Drug Administration. This mistaken belief ...

Heart safety of non-heart drugs questioned

Dec 29, 2007

A New York heart surgeon is calling for more testing to ensure the cardiovascular safety of drugs developed primarily for non-cardiovascular medical problems.

Recommended for you

New approach to particle therapy dosimetry

Dec 19, 2014

Researchers at the National Physical Laboratory (NPL), in collaboration with EMRP partners, are working towards a universal approach to particle beam therapy dosimetry.

Supplement maker admits lying about ingredients

Dec 17, 2014

Federal prosecutors say the owner and president of a dietary supplement company has admitted his role in the sale of diluted and adulterated dietary ingredients and supplements sold by his company.

User comments : 0

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.